CASI Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
CASI Pharmaceuticals's earnings have been declining at an average annual rate of -7.9%, while the Biotechs industry saw earnings growing at 16.9% annually. Revenues have been growing at an average rate of 60.5% per year.
Key information
-7.9%
Earnings growth rate
3.4%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 60.5% |
| Return on equity | -60.6% |
| Net Margin | -90.6% |
| Last Earnings Update | 31 Mar 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How CASI Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 23 | 42 | -38 | 39 | 15 |
| 31 Dec 22 | 43 | -41 | 38 | 16 |
| 30 Sep 22 | 37 | -27 | 39 | 16 |
| 30 Jun 22 | 35 | -32 | 39 | 15 |
| 31 Mar 22 | 33 | -31 | 39 | 13 |
| 31 Dec 21 | 30 | -37 | 38 | 14 |
| 30 Sep 21 | 26 | -45 | 35 | 14 |
| 30 Jun 21 | 22 | -52 | 34 | 14 |
| 31 Mar 21 | 17 | -54 | 30 | 14 |
| 31 Dec 20 | 15 | -48 | 27 | 11 |
| 30 Sep 20 | 12 | -47 | 27 | 10 |
| 30 Jun 20 | 10 | -40 | 29 | 9 |
| 31 Mar 20 | 8 | -46 | 30 | 10 |
| 31 Dec 19 | 4 | -46 | 30 | 9 |
| 30 Sep 19 | 3 | -43 | 27 | 11 |
| 30 Jun 19 | 0 | -42 | 25 | 11 |
| 31 Mar 19 | 0 | -32 | 22 | 10 |
| 31 Dec 18 | 0 | -27 | 18 | 9 |
| 30 Sep 18 | 0 | -23 | 14 | 9 |
| 30 Jun 18 | 0 | -16 | 7 | 8 |
| 31 Mar 18 | 0 | -13 | 4 | 8 |
| 31 Dec 17 | 0 | -11 | 4 | 7 |
| 30 Sep 17 | 0 | -8 | 4 | 5 |
| 30 Jun 17 | 0 | -8 | 4 | 5 |
| 31 Mar 17 | 0 | -9 | 5 | 4 |
| 31 Dec 16 | 0 | -9 | 5 | 4 |
| 30 Sep 16 | 0 | -8 | 4 | 4 |
| 30 Jun 16 | 0 | -8 | 4 | 4 |
| 31 Mar 16 | 0 | -7 | 3 | 4 |
| 31 Dec 15 | 0 | -7 | 4 | 4 |
| 30 Sep 15 | 0 | -7 | 4 | 3 |
| 30 Jun 15 | 0 | -27 | 4 | 3 |
| 31 Mar 15 | 0 | -27 | 4 | 3 |
| 31 Dec 14 | 0 | -26 | 4 | 3 |
| 30 Sep 14 | 0 | -26 | 4 | 2 |
| 30 Jun 14 | 0 | -6 | 3 | 2 |
| 31 Mar 14 | 0 | -6 | 3 | 3 |
| 31 Dec 13 | 0 | -6 | 3 | 3 |
| 30 Sep 13 | 1 | -5 | 3 | 2 |
| 30 Jun 13 | 1 | -5 | 3 | 2 |
| 31 Mar 13 | 1 | -13 | 2 | 2 |
| 31 Dec 12 | 1 | -15 | 3 | 2 |
| 30 Sep 12 | 2 | -14 | 3 | 2 |
| 30 Jun 12 | 2 | -14 | 3 | 2 |
Quality Earnings: YZ3 is currently unprofitable.
Growing Profit Margin: YZ3 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: YZ3 is unprofitable, and losses have increased over the past 5 years at a rate of 7.9% per year.
Accelerating Growth: Unable to compare YZ3's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: YZ3 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-26.8%).
Return on Equity
High ROE: YZ3 has a negative Return on Equity (-60.57%), as it is currently unprofitable.